| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Algeria Pharmaceuticals and Healthcare Report Q4 2009
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
Algeria |
Published |
27 August 2009 |
Number of Pages |
62 |
Download |
|
Immediate |
|
Publisher |
Business Monitor International |
Algeria's generics market was valued at US$0.89bn, accounting for just over 38% of the total pharmaceuticals market
In the Q409 Business Environment Rankings matrix for the 17 key countries of the Middle East and Africa (MEA) region, Algeria remains in a lowly 14th position. While its considerable population size (over 34mn and growing) and the substantial potential for healthcare investment provide some draws, low per-capita spending and wide-ranging deficiencies in its regulatory and pricing and reimbursement environment will continue to hamper major improvements in the country’s score. The country remains among the bottom ten markets of the 71 countries surveyed by the report globally. Nevertheless, depending on the wider economic climate, Algeria’s pharmaceutical expenditure should increase over the coming five years, from DZD159bn (US$2.35bn) in 2008 to reach DZD209bn (US$2.94bn) in 2013, growing at a compound annual growth rate (CAGR) of 5.62% in local currency terms.
The government has indicated its commitment to the improvement of its population’s health, outlining a programme through to 2025 which includes the expansion of hospital beds. While this situation will provide substantial opportunities to foreign players – most of which operate in the country through imports or local partnerships – they may be discouraged by the ban on imports of drugs that can be made locally, especially as the list of such drugs is to be extended from the start of 2010. Even though this will put the brakes on Algeria’s bid for World Trade Organization (WTO) membership, the government is keen to protect the local drug industry, which is mostly engaged in the manufacture of generics.
In fact, Algeria’s generics market is relatively advanced, having been stimulated by the government’s encouragement, lax intellectual property (IP) laws and the fact that public expenditure represents some 80% of total healthcare spending. In 2008, the country’s generics market was valued at an estimated DZD60.6bn (US$0.89bn), accounting for just over 38% of the total market by value, and up to two-thirds by volume terms. The requirement that generics account for 45% of all imports will support generics development over the longer term, especially as the longer-term target is the figure of 70%. Additionally, promoters of generics and local industry recently suggested that the social security should issue rebates to those using generic drugs. If implemented, the proposals have the potential to increase the penetration of generics to higher than forecast over the coming years, although low prices of such products will depress value growth.
In July 2009, the government reported that it would import 65mn swine influenza vaccines, with the Minister of Health adding that all of the seven cases of the virus diagnosed in the country were visitors from abroad. The vaccine for the A (H1N1) virus will be available free of charge, with Algeria judged by the government to be well-prepared for this eventuality. However, local press did not make it clear from where the vaccine would be imported, with many European countries recently announcing that they are likely to fast-track human trials for swine flu vaccine.
Last Viewed
Algeria Pharmaceuticals and Healthcare Report Q4 2009Thai President Foods Plc - Financial Analysis Review
Merkur DD (Bosnia and Herzegovina) - Company Profile
Ambit Properties Limited - Financial Analysis Review
Viacom Inc. - Financial and Strategic Analysis Review
Healthcare and Medical Company Profiles
Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
Genium Bionic Prosthetic System Represents the First Intuitive Knee
AdCare continues nursing facilities acquisitions strategy
AdCare Purchases US$27.3Mn Nursing Facilities in Arkansas to Drive Strong Revenue Growth
Micromet to Develop Blinatumomab with the National Cancer Institute
AstraZeneca to Develop Targacept’s Product Candidate AZD1446 as a Treatment for Alzheimer’s
Market Insights
Currently there are no Market Insights in this sector.
